Kemmitt, Paul D.
AstraZeneca (United Kingdom)
3 papers on CoChatORCID 0000-0002-5374-6557
Most cited papers
- Verified
Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor
Finlay, M. R. V., Anderton, M., Ashton, S., Ballard, P., Bethel, P. A., Box, M. R., Bradbury, R. H., Brown, S. J., Butterworth, S., Campbell, A., et al. (2014) · Journal of Medicinal Chemistry
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 636
- Verified
Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6
McCoull, W., Cheung, T., Anderson, E., Barton, P., Burgess, J., Byth, K., Cao, Q., Castaldi, M. P., Chen, H., Chiarparin, E., et al. (2018) · ACS Chemical Biology
Protein Degradation and InhibitorsLymphoma Diagnosis and Treatment
Cited by 139
- Verified
Discovery of a Potent, Selective, and Orally Efficacious Pyrimidinooxazinyl Bicyclooctaneacetic Acid Diacylglycerol Acyltransferase-1 Inhibitor
Birch, A. M., Birtles, S., Buckett, L. K., Kemmitt, P. D., Smith, G. J., Smith, T. J. D., Turnbull, A. V., & Wang, S. J. Y. (2009) · Journal of Medicinal Chemistry
Pharmacology and Obesity TreatmentLipid metabolism and biosynthesis
Cited by 77
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free